• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Why Acupuncture Is Going Mainstream in Medicine
When the opioid addiction crisis began to surge in the U.S. about a decade ago, Dr. Medhat Mikhael spent a lot of time talking to his patients about other ways to heal pain besides opioids, from other types of medications to alternative treatments. As a pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, Calif., he didn’t anticipate leaving behind the short-term use of opioids altogether, since they work so well for post-surgical pain. But he wanted to recommend a remedy that was safer and still effective. That turned out to be acupuncture. “Like any treatment, acupuncture...
Source: TIME: Health - April 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate medicine Source Type: news

Neuroimaging and Neurolaw: Drawing the Future of Aging
Vincenzo Tigano1, Giuseppe Lucio Cascini2, Cristina Sanchez-Castañeda3, Patrice Péran4 and Umberto Sabatini5* 1Department of Juridical, Historical, Economic and Social Sciences, University of Magna Graecia, Catanzaro, Italy 2Department of Experimental and Clinical Medicine, University of Magna Graecia, Catanzaro, Italy 3Department of Clinical Psychology and Psychobiology, University of Barcelona, Barcelona, Spain 4ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France 5Department of Medical and Surgical Sciences, University of Magna Graecia, Catanzaro, ...
Source: Frontiers in Endocrinology - April 7, 2019 Category: Endocrinology Source Type: research

Stroke like migraine attacks after radiation therapy (SMART) syndrome a case series of three patients (P6.179)
Conclusions:Our patients represent the first case series of SMART syndrome in a single institution. Our cases share similarities to the prior reports in the literature and highlights the clinical and MRI triad of acute onset headaches, neurological deficits and MRI findings of transient contrast enhancement of the cortex with white matter sparing in a previous radiation field.Disclosure: Dr. rauf has nothing to disclose. Dr. Boulter has nothing to disclose. Dr. Imitola has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Rauf, Y., Boulter, D., Imitola, J. Tags: Neurologic Complications of Cancer Source Type: research

Stroke-like migraine attacks in long term survivors of high grade glioma. (P1.174)
Conclusions:Stroke-like migraine attacks are difficult to treat and the pathophysiology is unknown. With more sophisticated imaging techniques, a better understanding of this phenomenon will aid in the treatment and prophylaxis of the syndrome with a goal of improving quality of life for this small but slowly growing population.Disclosure: Dr. New has nothing to disclose. Dr. Mirza has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: New, P., Mirza, H. Tags: Neuro-oncology: Gliomas I Source Type: research

Atim-18. phase i dose escalation study of d2c7-it administered intratumorally via convection-enhanced delivery (ced) for recurrent malignant glioma (mg)
CONCLUSION:Infusion of D2C7-IT via CED is safe thus far and encouraging efficacy results are observed. Enrollment is ongoing.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., Bigner, D. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research